Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study

Table 5 Types of treatment centers associated with treatment response after topotecan and cyclophosphamide containing induction therapy (multivariate analysis)

Health care system	Response ≥ 90%	Response < 90%	Crude OR (95% CI)	p-value	Adjusted OR (95% CI)	p-value
University-based	37 (45.7)	44 (54.3)	1		1
Community-based	5 (19.2)	21 (80.8)	3.53 (1.21–10.28)	0.021	3.13 (1.05–9.37)	0.041

Notes: Data are categorical variables and presented as number (%). Multivariate analysis was calculated using multiple logistic regression adjusted for age, gender, grade of tumor differentiation, MYCN status, Shimada histology, serum NSE and urine VMA. p-value < 0.05 is considered as statistical significance

ISSN: 1471-2407